Fibrin degradation product (FDP)

Fibrin degradation products (FDPs) are protein fragments, such as D-dimer and Fragments D and E, that are released into the circulation when the enzyme plasmin cleaves cross-linked fibrin or fibrinogen (StatPearls, NBK537153). They serve as essential clinical biomarkers for the diagnosis and management of thrombotic disorders, including deep vein thrombosis, pulmonary embolism, and disseminated intravascular coagulation (DIC) (NIH, PMC5503938). While FDPs are primarily considered metabolic byproducts of fibrinolysis rather than direct therapeutic targets, they possess intrinsic biological activities that can influence platelet function, stimulate inflammatory cytokine release, and modulate angiogenesis (PubMed, 3063348). In pharmacological contexts, the concentration of FDPs is used to monitor the efficacy of thrombolytic agents like alteplase, which accelerate the breakdown of clots and consequently increase FDP levels (ScienceDirect, Fibrin Degradation Product). High levels of FDPs are also associated with poor prognosis in various conditions, including severe infection and malignancy, reflecting systemic activation of the coagulation cascade.

Other names

Fibrin split productsFSPD-dimerFragment DFragment EX-oligomers

Fibrin degradation products are produced by the enzymatic cleavage of fibrin by plasmin; thrombolytic drugs activate plasminogen to increase plasmin activity, thereby generating these products to dissolve blood clots.